Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
PHASE2CompletedINTERVENTIONAL
Enrollment
54
Participants
Timeline
Start Date
October 31, 2005
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
Conditions
Metastatic Breast Cancer
Interventions
DRUG
Ixabepilone
Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles